ErVimmune, founded in Lyon in 2019 as ErVaccine Technologies and based at the Centre Léon Bérard cancer centre, targets human endogenous retroviruses, remnants of ancient viral infections in the human genome that are normally silent but switch on in cancer cells and can mark them for the immune system. It was selected in the EIC Accelerator's June 2023 cut-off with blended finance and received an EU grant of €2.50 million for OVACell, a €3.65 million project from March 2024 to April 2026 to develop TCR-OV1, an engineered T-cell therapy for ovarian cancer, according to CORDIS. The company planned "clinical validation of TCR-OV1's efficacy and safety in patients" in the fourth quarter of 2027.
The only public report, to November 2024, says an extended animal study "revealed suboptimal anti-tumor activity of TCR-OV1": tumour growth slowed for three weeks, but by day 50 "tumor volumes were identical in both the treated group and the control group", according to the CORDIS reporting page. Knocking out the cells' own receptor improved binding, but a new gene insertion method brought no reproducible gain in killing tumour cells, and the company said the extra steps needed "will result in a significant delay and additional cost". In January 2026 chief executive Nathalie Donne said the T-cell programme "is still in research with an academic collaboration to optimize T cell engineering", while the company's €17 million Series A went to its vaccine ErVac01, according to European Biotechnology Magazine.
Company file
- Legal entity
- ErVimmune SAS, SIREN 877 916 213, Lyon
- CEO
- Nathalie Donne
- Founder
- Stéphane Depil, board member
- EIC product
- TCR-OV1, T-cell therapy for ovarian cancer
- Lead product now
- ErVac01 cancer vaccine
- Investors
- Seventure Partners, SPRIM Global Investments
- EIC funding
- Blended finance
Where ErVimmune Stands Now
ErVimmune closed the first €17 million of its Series A in January 2026 with existing shareholder Seventure Partners and new investor SPRIM Global Investments of Singapore, to bring its off-the-shelf vaccine into a first human trial, according to EU-Startups. The vaccine targets triple-negative breast cancer and ovarian cancer. The announcements do not mention the EIC Fund. A capital change was registered in February 2026, and ErVimmune files its accounts confidentially, according to BODACC.
"This program is still in research with an academic collaboration to optimize T cell engineering."
Nathalie Donne, CEO, to European Biotechnology Magazine, January 2026The Technology: Old Viruses as Cancer Targets
Ovarian cancer is the deadliest gynaecological cancer, and most patients are diagnosed late. ErVimmune's software finds fragments of retroviral proteins made only by cancer cells and shared by many patients, so one product could treat many people. TCR-OV1 equips a patient's T cells with a receptor that recognises one such fragment. The report says the target is overexpressed in ovarian tumours and that regulators at the FDA and EMA agreed in a preliminary meeting that such targets "may be of interest to be evaluated in the clinic".
What the EIC Award Promised, and What the Record Shows
The award aimed to take TCR-OV1 toward the clinic, with patient data expected in late 2027. Within the first nine months the therapy failed to control tumours over time. The company tried re-engineering the cells, began work on co-receptors and proposed a different format, T-cell engagers. By the end of the project the programme had returned to academic research and investors had backed a different product.
- Target specificityDeliveredProteomics confirmed.
- Durable anti-tumour effectNot deliveredLost by day 50.
- Regulatory dialogueStartedPreliminary FDA and EMA meeting.
- Clinical readinessNot deliveredBack in research.
The Money
The EU covered 68% of the project. Whether the EIC Fund invested under the blended award is not public; its name does not appear in the Series A announcements. The Series A is almost seven times the EU grant and is earmarked for the vaccine.
What Cannot Be Checked
Questions for the EIC
Whether the EIC agreed to redirect the project, whether any of the grant funded vaccine work, whether the EIC Fund invested, and what the final report says are not public.
Why Europe Should Care
Long-term efficacy of T-cell therapies "is a challenge in solid tumors", ErVimmune's report notes. ErVimmune's report is candid about why TCR-OV1 fell short, which is useful to the field. For the EIC, it is a case of funding a product that did not survive its first serious test, while the company's investors moved on.
What the award promised
A T-cell therapy for ovarian cancer on its way to patient trials.
What the record shows
An effect that faded in animals, a programme back in research and a Series A for a vaccine.
The Verdict
Honest failure
ErVimmune reported openly that TCR-OV1 did not work well enough. The product the EIC funded is no longer the company's priority.
ErVimmune and the EIC have not been asked for comment for this article. It is based entirely on public records and published statements, linked throughout.
